Literature DB >> 8761194

The cost of rheumatoid arthritis.

E McIntosh1.   

Abstract

This paper uses the Cost of Illness (COI) framework to estimate the cost of rheumatoid arthritis (RA) to society in the year 1992-93. By doing so, a clear insight is given into the many cost elements of RA treatment and monitoring. This paper estimates point prevalence rates of 2.06 and 6.94 1000 persons at risk for men and women, respectively, showing that prevalence is three times higher amongst women than men. Further to this, prevalence increases with age in both sexes, resulting in very high prevalence rates for RA amongst the elderly. The total economic impact of RA in England was estimated to be pounds 1.256 billion in 1992, of which 52% was a result of production loss caused by RA disability.

Entities:  

Mesh:

Year:  1996        PMID: 8761194     DOI: 10.1093/rheumatology/35.8.781

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  25 in total

Review 1.  Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis?

Authors:  R M Lowenthal; S R Graham
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

Review 2.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 3.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 4.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

7.  The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.

Authors:  Marco Barbieri; John B Wong; Michael Drummond
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F)).

Authors:  Anna Moverley; Laura Coates; Helena Marzo-Ortega; Robin Waxman; David Torgerson; Kim Cocks; Judith Watson; Philip S Helliwell
Journal:  Clin Rheumatol       Date:  2015-02-03       Impact factor: 2.980

9.  A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

Authors:  M J Nuijten; P Engelfriet; K Duijn; G Bruijn; D Wierz; M Koopmanschap
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

10.  Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK.

Authors:  C J McCabe; R L Akehurst; J Kirsch; M Whitfield; M Backhouse; A D Woolf; D L Scott; P Emery; I Haslock
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.